tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Unicycive Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $9 price target Unicycive is a clinical stage biotechnology company developing novel therapies for treating kidney diseases, the analyst tells investors in a research note. The firm expects a positive decision by the FDA for the company’s leading clinical candidate, oxylanthanum carbonate, for lowering high phosphate levels or hyperphosphatemia in chronic kidney disease patients undergoing dialysis and expects management to launch the drug by the end of 2025.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1